Frontline AML: The All-Oral Evolution & Real-World Resilience

Amer Zeidan, MBBS, MD, discusses how the newly approved all-oral decitabine/cedazuridine plus venetoclax regimen fits into frontline AML care.

Amer Zeidan, MBBS, MD, discusses why real-world venetoclax dose modifications do not appear to compromise response durability in AML.

Amer Zeidan, MBBS, MD, discusses how mutation status and physical fitness factor into frontline AML regimen selection.

Amer Zeidan, MBBS, MD, discusses whether the expanding lower-intensity arsenal has narrowed the definition of a patient with AML who is unfit.

Courtney D. DiNardo, MD, MSCE, and Michael R. Savona, MD, discussed how fast oral DEC-C plus venetoclax may replace IV HMA regimens in AML.

Michael R. Savona, MD, and Courtney D. DiNardo, MD, MSCE, explained how an all-oral AML regimen impacts infusion center logistics and patient visits.

Courtney D. DiNardo, MD, MSCE; and Michael R. Savona, MD, weigh whether ASCERTAIN-V data make oral HMA therapy the frontline default in AML.

Michael R. Savona, MD, and Courtney D. DiNardo, MD, MSCE, discussed ARC initiative data on venetoclax dose modifications in AML.

Courtney D. DiNardo, MD, MSCE, and Michael R. Savona, MD, shared antiemetic strategies for GI AEs with oral AML regimens.

Michael R. Savona, MD, and Courtney D. DiNardo, MD, MSCE, discussed overcoming insurance barriers to oral AML treatment access.